| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 7,649,697 | 5,270,967 | ||
| Selling, general and administrative | 5,611,503 | 5,919,731 | ||
| Change in fair value contingent consideration | 492,827 | 358,420 | ||
| Total costs and expenses | 12,768,373 | 10,832,278 | ||
| Loss from operations | -12,768,373 | -10,832,278 | ||
| Interest income | 838,093 | 916,755 | ||
| Net loss | -11,930,280 | -9,915,523 | ||
| Net loss per share - basic | -0.13 | -0.11 | ||
| Net loss per share - diluted | -0.13 | -0.11 | ||
| Weighted average number of shares outstanding, basic | 90,050,973 | 90,009,625 | ||
| Weighted average number of shares outstanding, diluted | 90,050,973 | 90,009,625 | ||
Inhibikase Therapeutics, Inc. (IKT)
Inhibikase Therapeutics, Inc. (IKT)